Sibel ANNE Maternal FDA 510(k) — First Fully Wireless Maternal-Fetal Monitoring. US Maternal Mortality 22/100k Blind Spot
BODY

Sibel ANNE Maternal FDA 510(k) — First Fully Wireless Maternal-Fetal Monitoring. US Maternal Mortality 22/100k Blind Spot

By Polly · · Sibel Health / FDA 510(k)
KO | EN

US maternal mortality is 22/100,000 — highest among developed countries, 2x+ others. Maternal·fetal monitoring done bed-bound. Sibel Health 2026.4.9 FDA 510(k) clearance = first fully wireless maternal-fetal integrated monitoring.

Key Announcement

ANNE Maternal: First fully wireless maternal-fetal monitoring, FDA 510(k) clearance 2026.4.9, measurements: mother (HR·RR·temp·BP) + fetus (HR·uterine contractions), patch form (skin adhesion), wireless (Bluetooth·LTE)

Gates Foundation 2026 Annual Letter Listing: India·Pakistan·Nigeria·Rwanda 4-country deployment, low-resource·high-risk mother priority

US Maternal Mortality - Blind Spot

US maternal mortality: 22/100,000 (2021~), developed countries worst, 2x+ others (Australia·UK·Canada 5~7/100k), Black mothers = 3x white, Latino mothers ↑

Causes: Healthcare access gap, racial·economic gap, inadequate monitoring, PPD·cardiovascular·hypertension integrated care lacking

Korean Maternal Mortality

Korea: 11.7/100,000 (2021), developed countries average, but ↓ birth rate + ↑ older mothers → ↑ risk

High-risk mother increase: 35+ mothers ↑, pregnancy complications (diabetes·hypertension), autoimmune, obesity

ANNE Maternal - New Dimension

Existing monitoring: Bed-bound, wires·belts, clinician each measurement, ↓ mobility

ANNE Maternal: Wireless patch (5~10), continuous monitoring (24/7), mother free mobility, cloud data (clinician remote), AI anomaly detection

Measurements

Mother: HR, RR, temp, BP, SpO2, posture·activity

Fetus: FHR, uterine contractions, fetal movement, (planned) fetal SpO2

Gates Foundation - Global Maternal Health

2026 Annual Letter: Maternal health priority, ANNE Maternal listed, India·Pakistan·Nigeria·Rwanda 4-country deployment

Global mortality: India 103/100k, Pakistan 154/100k, Nigeria 1,047/100k (world’s worst), Rwanda 248/100k → wireless·low-cost monitoring urgent

L72 Digital Verification·Establishment Dimension - 3rd Axis

Maternal·postpartum digital integration complete. Antenatal→delivery→postpartum digital care matrix.

Korean Implications

Current Korea: Pre·post-delivery bed monitoring (wire·belt), wireless partial (Monica·Bloomlife), postpartum monitoring lacking, ↑ older mothers

ANNE Maternal expected: FDA → Korean MFDS 1~2 yr, 2027 expected, price $5,000~$15,000 (hospital), OB-GYN adoption

Postpartum Monitoring - Blind Spot

Postpartum risks: 6-wk hemorrhage, PPD·suicide, postpartum cardiovascular (preeclampsia progression), postpartum thrombosis

Current care limits: Postpartum 1~2 visits, no 24/7 monitoring, emergency detection delay

ANNE Maternal postpartum: Postpartum 1~6 wk self-monitoring, anomaly detection → instant alert, home possible

Pregnancy Stage Guide

1st Trimester: Regular OB-GYN, nutrition·exercise, drug·environment avoidance

2nd Trimester: Precision ultrasound, gestational diabetes screening, partial monitoring start

3rd Trimester: Frequent monitoring, fetal HR·uterine contractions, ANNE Maternal possible (hospital·home)

Delivery: ANNE Maternal continuous, free mother mobility, clinician remote tracking

Postpartum (1~6 wk): 6-week checkup, ANNE Maternal self-use (hemorrhage·BP), PPD EPDS evaluation

Maternal digital health: Bloomlife (uterine), Owlet (fetal), Mira (hormones·fertility), Maven Clinic (telehealth), Sibel ANNE Maternal (L72) — first fully wireless integrated

FAQ

Q. ANNE Maternal home use possible? A. FDA approval = hospital·clinical environment. Future home expansion expected. Currently delivery hospital·partial postpartum home possible.

Q. Wireless accurate? A. FDA 510(k) verifies accuracy. Equivalent or superior to wire. But signal loss monitoring needed.

Q. Korea availability? A. Korean MFDS medical device review. 2027 expected. University hospital·OB-GYN priority adoption.

Q. General mothers usable? A. FDA = clinical. Future general mother expansion possible. Currently high-risk priority.

Q. Gates Foundation 4-country relevance to Korea? A. Global maternal health gap visualization. Korea low mortality but postpartum care·high-risk mother area improvement room.

Conclusion

Sibel ANNE Maternal FDA 510(k) = first fully wireless maternal-fetal integrated monitoring. Digital solution enters US maternal mortality 22/100k blind spot. L72 = 45 pillars + digital verification·establishment dimension (maternal monitoring 3rd axis). Gates Foundation global deployment. Korea adoption 2027. Era of mothers not bound to beds.

Source: Sibel Health / FDA 510(k)